Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407212 · ClinicalTrials.gov registry record · Phase 1
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 301
- Enrollment target
NCT00407212 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 301 participants.
The verdict
NCT00407212, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 301 participants
- Enrollment target
Study Summary
This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
Interventions
- DRUG TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407212
The ClinicalTrials.gov registry entry for NCT00407212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) is the first listed.
NCT00407212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00407212 about?
NCT00407212 is a clinical study titled "A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy". This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
What is the current status of trial NCT00407212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 301 participants. The study started on 2002-01. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00407212?
The interventions under investigation include: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) (DRUG).
Who is sponsoring clinical trial NCT00407212?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.